Condition Lookup

Glioblastoma Multiforme (GBM)

Specialty: Oncology

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
headaches; nausea; vomiting; seizures; neurological deficits (e.g., weakness, vision changes); cognitive or personality changes; speech difficulties

Root Cause:
Uncontrolled proliferation of astrocytes, leading to a highly aggressive and infiltrative malignant tumor in the brain.

How it's Diagnosed: videos
Magnetic Resonance Imaging (MRI) with contrast, biopsy for histopathological confirmation, molecular testing (e.g., MGMT promoter methylation, IDH mutation status).

Treatment:
Surgery for tumor resection, followed by radiotherapy and temozolomide chemotherapy. Experimental treatments include targeted therapies, tumor-treating fields (TTFields), and immunotherapy.

Medications:
Temozolomide (alkylating agent), bevacizumab (anti-VEGF monoclonal antibody), corticosteroids like dexamethasone (to reduce cerebral edema).

Prevalence: How common the health condition is within a specific population.
Accounts for approximately 15% of all primary brain tumors; incidence is 3.19 cases per 100,000 individuals annually.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Advanced age, male gender, exposure to ionizing radiation, history of certain genetic disorders (e.g., Li-Fraumeni syndrome, Turcot syndrome).

Prognosis: The expected outcome or course of the condition over time.
Poor prognosis; median survival is 15-18 months with standard therapy, and 5-year survival rates are below 10%.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Cerebral edema, increased intracranial pressure, neurological deficits, cognitive decline, seizures, recurrence of tumor.

Astrocytomas

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
headaches; seizures; neurological deficits such as weakness or vision changes; personality or cognitive changes; nausea and vomiting

Root Cause:
Tumors arising from astrocytes, which are star-shaped glial cells in the brain and spinal cord. These tumors vary in malignancy, from low-grade (Grade I-II) to high-grade (Grade III-IV).

How it's Diagnosed: videos
MRI with contrast for visualization, histopathology from biopsy, molecular analysis for IDH mutation and 1p/19q co-deletion (in relevant cases).

Treatment:
The treatment for astrocytomas depends on the grade and location of the tumor and typically includes - Surgery - Surgical resection to remove as much of the tumor as possible while preserving neurological function. Radiation Therapy - Used post-surgery for high-grade astrocytomas or when complete resection is not possible. Chemotherapy - Temozolomide is commonly used for high-grade astrocytomas like glioblastomas. Targeted Therapy - Bevacizumab may be used for recurrent cases to inhibit tumor-associated angiogenesis. Supportive Care - Includes corticosteroids to reduce brain swelling and anticonvulsants for seizure control.

Medications:
Temozolomide (alkylating agent), lomustine (alkylating agent), corticosteroids like dexamethasone to manage swelling and edema.

Prevalence: How common the health condition is within a specific population.
Astrocytomas represent approximately 25% of all primary CNS tumors. Low-grade astrocytomas are more common in younger patients, while high-grade ones are more prevalent in adults.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition (e.g., Li-Fraumeni syndrome, Neurofibromatosis), exposure to ionizing radiation, male gender, increasing age (for high-grade astrocytomas).

Prognosis: The expected outcome or course of the condition over time.
Prognosis varies significantly by grade

Complications: Additional problems or conditions that may arise as a result of the original condition.
Tumor progression, recurrence, neurological deficits, increased intracranial pressure, seizures.

Meningiomas

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
headaches; seizures; focal neurological deficits (e.g., weakness, vision changes); personality or cognitive changes

Root Cause:
Tumors arising from the meninges (membranes surrounding the brain and spinal cord); most are benign but can occasionally be atypical or malignant.

How it's Diagnosed: videos
MRI with contrast or CT scan, biopsy for histopathological confirmation (if necessary).

Treatment:
Observation for asymptomatic, slow-growing tumors; surgery for symptomatic or accessible tumors; radiotherapy for inoperable or recurrent cases.

Medications:
No standard chemotherapy; corticosteroids (e.g., dexamethasone ) may be used for symptom relief.

Prevalence: How common the health condition is within a specific population.
The most common primary brain tumor, accounting for about 30% of all CNS tumors, with higher incidence in middle-aged to elderly adults.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Female gender (linked to hormonal factors), exposure to ionizing radiation, genetic disorders (e.g., Neurofibromatosis Type 2).

Prognosis: The expected outcome or course of the condition over time.
Benign meningiomas have an excellent prognosis with surgery (5-year survival >90%); atypical or malignant types have worse outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Neurological deficits, tumor recurrence, malignant transformation (rare).

Oligodendrogliomas

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
seizures; headaches; cognitive difficulties; weakness or paralysis; personality changes

Root Cause:
Tumors arising from oligodendrocytes, the glial cells responsible for myelin production in the CNS. Often associated with 1p/19q co-deletion and IDH mutations.

How it's Diagnosed: videos
MRI with contrast, biopsy with histopathological examination, molecular testing for 1p/19q co-deletion and IDH mutation.

Treatment:
Surgical resection, followed by radiotherapy and chemotherapy (PCV regimen

Medications:
PCV regimen (procarbazine , lomustine , vincristine ), temozolomide , corticosteroids like dexamethasone for symptom relief.

Prevalence: How common the health condition is within a specific population.
Rare, accounting for approximately 2-5% of all primary brain tumors.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic mutations (1p/19q co-deletion, IDH mutation), exposure to ionizing radiation, family history of gliomas.

Prognosis: The expected outcome or course of the condition over time.
Better prognosis than glioblastomas; median survival for Grade II is >10 years, and for Grade III, 3-6 years with appropriate treatment.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Seizures, neurological deficits, tumor recurrence, malignant progression.

Ependymomas

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
headaches; nausea; vomiting; hydrocephalus-related symptoms (e.g., balance issues, gait problems); visual disturbances; back pain (if spinal cord involvement)

Root Cause:
Tumors arising from ependymal cells lining the ventricles of the brain and the central canal of the spinal cord.

How it's Diagnosed: videos
MRI with contrast, biopsy for histological confirmation, cerebrospinal fluid (CSF) analysis for metastatic disease.

Treatment:
Surgical resection, followed by radiotherapy; chemotherapy in select cases (especially in pediatric patients).

Medications:
Corticosteroids (e.g., dexamethasone ) for symptom management, chemotherapy agents like cisplatin and vincristine in some pediatric cases.

Prevalence: How common the health condition is within a specific population.
Rare, accounting for 2-3% of all primary brain tumors; more common in children than adults.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic syndromes (e.g., Neurofibromatosis Type 2), exposure to ionizing radiation.

Prognosis: The expected outcome or course of the condition over time.
Prognosis varies by grade and resectability; 5-year survival rates for Grade II are 50-70%, while higher-grade tumors have poorer outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Hydrocephalus, neurological deficits, tumor recurrence, metastatic spread in the CNS.

Medulloblastomas

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
headaches; nausea and vomiting; balance and coordination problems; visual disturbances (e.g., double vision); lethargy

Root Cause:
Aggressive, embryonal tumor originating in the cerebellum, often spreading through the cerebrospinal fluid (CSF). Most common in pediatric patients.

How it's Diagnosed: videos
MRI with contrast, biopsy, CSF analysis for metastasis, molecular subgrouping (e.g., WNT, SHH subtypes).

Treatment:
Surgery for maximal safe resection, followed by craniospinal radiotherapy and chemotherapy. Molecular-targeted therapy is emerging for specific subgroups.

Medications:
Chemotherapy agents like cisplatin , vincristine , and cyclophosphamide ; corticosteroids (e.g., dexamethasone ) for symptom management.

Prevalence: How common the health condition is within a specific population.
Accounts for 20% of all pediatric brain tumors, with peak incidence between ages 3-8 years.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition (e.g., Gorlin syndrome, Turcot syndrome), family history of CNS tumors.

Prognosis: The expected outcome or course of the condition over time.
Prognosis depends on molecular subtype and extent of metastasis; 5-year survival rates range from 50% (high-risk cases) to 80% (low-risk cases).

Complications: Additional problems or conditions that may arise as a result of the original condition.
Neurological deficits, hydrocephalus, endocrine dysfunction, learning disabilities, tumor recurrence.

Pituitary Tumors

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
visual disturbances (e.g., bitemporal hemianopsia); headaches; hormonal imbalances (e.g., cushing’s syndrome, acromegaly); fatigue; nausea and vomiting

Root Cause:
Tumors arising from the pituitary gland; may be functional (hormone-secreting) or non-functional.

How it's Diagnosed: videos
MRI with contrast, hormonal blood tests, visual field testing.

Treatment:
Surgery (transsphenoidal resection), medical therapy for functional tumors (e.g., dopamine agonists for prolactinomas), radiotherapy for residual or recurrent cases.

Medications:
Dopamine agonists (e.g., cabergoline , bromocriptine ) for prolactinomas; somatostatin analogs (e.g., octreotide ) for growth hormone-secreting tumors.

Prevalence: How common the health condition is within a specific population.
Relatively common, accounting for about 10-15% of all primary brain tumors.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of pituitary tumors, genetic conditions like Multiple Endocrine Neoplasia Type 1 (MEN1).

Prognosis: The expected outcome or course of the condition over time.
Prognosis depends on tumor type and resectability; functional tumors may require long-term medical management.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Hormonal imbalances, vision loss, recurrence, hypopituitarism following treatment.

Primary CNS Lymphoma

Specialty: Oncology

Category: Solid Tumors

Sub-category: Central Nervous System (CNS) Tumors

Symptoms:
headaches; cognitive impairment; neurological deficits; seizures; blurred vision or eye pain; weakness

Root Cause:
High-grade non-Hodgkin lymphoma originating within the CNS, often involving the brain, spinal cord, or eyes.

How it's Diagnosed: videos
MRI with contrast, biopsy for histological confirmation, CSF analysis, and blood tests for systemic lymphoma exclusion.

Treatment:
High-dose methotrexate-based chemotherapy, sometimes combined with rituximab; whole-brain radiotherapy is considered for refractory cases.

Medications:
High-dose methotrexate (antimetabolite), rituximab (anti-CD20 monoclonal antibody), corticosteroids (e.g., dexamethasone ) for symptom control.

Prevalence: How common the health condition is within a specific population.
Rare, accounting for approximately 1% of all primary brain tumors, more common in immunocompromised individuals.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Immunosuppression (e.g., HIV/AIDS, organ transplantation), Epstein-Barr virus (EBV) infection.

Prognosis: The expected outcome or course of the condition over time.
Prognosis has improved with methotrexate-based treatment; median survival is 2-5 years. Relapse is common.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Neurological deficits, tumor recurrence, systemic spread (rare), treatment-related neurotoxicity.